Abstracts tagged "SLE"

Abstract Number: 1585 • 2017 ACR/ARHP Annual Meeting
Role of Corticosteroids in Subclinical Atherosclerosis in SLE: A Systematic Review and Meta-Analysis
Ehsan Rajabirostami¹, Kam Newman², Sreelakshmi Panginikkod¹, Shahrzad Mohammadiankhansari¹, Nader Mehri³, Roshanak Habibi⁴ and Manish Jain⁵, ¹Internal Medicine, Presence Saint Francis Hospital, Evanston, IL, ²Rheumatology, Eisenhower Medical Center, Rancho Mirage, CA, ³Social Gerontology, Miami University, Oxford, OH, ⁴Presence Saint Francis Hospital, Evanston, IL, ⁵Rheumatology, Presence Saint Francis Hospital, Evanston, IL
Background/Purpose: Atherosclerosis in SLE results from a complex interplay between traditional risk factors, SLE-specific factors, chronic inflammation and multifaceted effects of SLE therapeutics. In particular,…
Abstract Number: 1811 • 2017 ACR/ARHP Annual Meeting
Lupus Patients, and Their Sisters, Have Higher Miscarriage Rates Than Healthy Women
Eliza Chakravarty¹, David Miklos², Nathan Pezant³, Fang Wu², Indra Adrianto⁴, R. Hal Scofield³, Joel M. Guthridge⁵, Courtney Montgomery⁴ and Judith A. James⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Hematology, Stanford University, Stanford, CA, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, OKC, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that primarily affects women during the childbearing years. Among its protean manifestation, pregnancy complications including…
Abstract Number: 2611 • 2017 ACR/ARHP Annual Meeting
Walk SLE – a Pilot Study Exploring Walk with Ease (WWE), a Self-Directed Walking Program, in Lupus Patients
Brittaney-Belle E. Gordon¹, Katherine Kaufman², Sean T. Hicks¹, Julie A. Norfleet¹, Rebecca J. Cleveland¹, Leigh F. Callahan³ and Saira Z. Sheikh¹, ¹Thurston Arthritis Research Center, University of North Carolina School of Medicine, Chapel Hill, NC, ²Department of Pediatrics, Duke University School of Medicine, Durham, NC, ³Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Fatigue and arthritis are common sources of impairment in SLE patients that persist despite lifestyle and pharmacologic interventions. Walk with Ease (WWE) is the…
Abstract Number: 698 • 2017 ACR/ARHP Annual Meeting
Selected Nailfold Videocapillaroscopy Changes Are Linked to SLE Onset in a Cohort of Uctd Subjects
Marianna Meroni¹, Carmen Pizzorni², Alberto Sulli¹, Paola Rossi³, Paolo Stobbione³ and Maurizio Cutolo⁴, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genova, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino, Genoa, Italy, Genoa, Italy, ³Rheumatology Unit, Internal Medicine Department - A.O. S.S. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genoa, Italy
Background/Purpose: Nailfold capillaroscopy (NVC) is a useful, non-invasive, reproducible and cost-effective diagnostic tool, able to assess the shape of capillaries in the nailfold bed. According…
Abstract Number: 1586 • 2017 ACR/ARHP Annual Meeting
Resistant Hypertension Is Associated with Inflammation, Renal Function, and Increased Mortality in Patients with Systemic Lupus Erythematosus
Jocelyn Gandelman¹, Megan Shuey², April Barnado³, Li Wang⁴, C. Michael Stein³ and Cecilia P. Chung³, ¹Vanderbilt University School of Medicine, Nashville, TN, ²Department of Pharmacology, Vanderbilt University, Nashville, TN, ³Medicine, Vanderbilt University Medical Center, Nashville, TN, ⁴Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Resistant hypertension (RHTN) is defined as blood pressure that remains >140/90 mm Hg despite concurrent use of three different antihypertensive drugs. RHTN has an…
Abstract Number: 1834 • 2017 ACR/ARHP Annual Meeting
Selective Inhibitors of Nuclear Export Prevent Lupus Progression By Targeting Germinal Center Formation and Autoreactive Antibody Secreting Cells
Javier Rangel-Moreno¹, Jennifer Barnard², Shelton Cochran³, Margaret Lee³, Sharon Tamir³ and Jennifer H. Anolik⁴, ¹Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Medicine-Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ³Karyopharm Therapeutics, Newton, MA, ⁴Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: There is great interest in developing new treatment approaches for systemic lupus erythematosus (SLE), but the biologic therapies under investigation over the past several…
Abstract Number: 2618 • 2017 ACR/ARHP Annual Meeting
Why Aren’t All Patients with SLE Taking Hydroxychloroquine? A Retrospective Chart Review
Caroline H. Siegel¹, Jennifer M. Grossman¹, John Fitzgerald¹, Bevra H. Hahn^1,2, Lori Sahakian¹, Eloise Olmos² and Maureen A. McMahon¹, ¹UCLA David Geffen School of Medicine, Los Angeles, CA, ²Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Although previous SLE treatment guidelines recommended judicious use of antimalarials, there is a growing body of evidence demonstrating that HCQ prevents flares, protects against…
Abstract Number: 706 • 2017 ACR/ARHP Annual Meeting
Elevated Erythrocyte Sedimentation Rate Among Obese Patients with SLE- Not Always a Marker of Disease Activity
George Stojan¹, Erik Barr² and Michelle Petri³, ¹Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, ³Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD
Background/Purpose: Obesity is more common in patients with SLE compared to the general population. The prevalence of obesity among SLE patients is between 28 and…
Abstract Number: 1597 • 2017 ACR/ARHP Annual Meeting
Arthritis and Hydroxychloroquine Are Associated with Decreased Risk of Macrophage Activation Syndrome Among Adults Hospitalized with SLE
Kristin D'Silva¹, Ezra Cohen², David J. Kreps³, Mary Beth Son² and Karen H. Costenbader³, ¹Internal Medicine, Brigham and Women's Hospital, Boston, MA, ²Boston Children's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Macrophage activation syndrome (MAS) is an uncommon but potentially fatal complication of SLE. We conducted a case-control study comparing hospitalized adults with SLE with…
Abstract Number: 1835 • 2017 ACR/ARHP Annual Meeting
Microglial Defects Contribute to Neuropsychiatric Symptoms of Systemic Lupus Erythematosus
Hadijat Makinde¹, Philip J. Homan², Harris Perlman² and Carla Cuda², ¹Northwestern University, Chicago, IL, ²Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Neuropsychiatric symptoms of systemic lupus erythematosus (NP-SLE), including headaches, cognitive dysfunction and psychiatric disorders, appear in up to 75% of SLE patients and may…
Abstract Number: 2632 • 2017 ACR/ARHP Annual Meeting
The Southern California Lupus Registry: I. Baseline Characteristics of Patients with Systemic Lupus Erythematosus in an Uncharted Territory
Joshua Liu¹, Kathleen Teves², Van La², Arlene Bravo³, Sheila Lezcano⁴, Talha Khawar⁴, Ebrahim Sadeghi⁴, Cong-Bin Wang⁵, Karina Torralba⁶, Howard Yang⁵ and Vaneet K. Sandhu⁷, ¹Internal Medicine, Loma Linda University Medical Center, Loma Linda, CA, ²Internal Medicine, University of California, Riverside, Riverside, CA, ³Internal Medicine, Loma Linda University, Loma Linda, CA, ⁴Rheumatology, Loma Linda University Medical Center, Loma Linda, CA, ⁵Loma Linda University Medical Center, Loma Linda, CA, ⁶Internal Medicine/Rheumatology, Loma Linda University, Loma Linda, CA, ⁷Division of Rheumatology, Loma Linda University, Loma Linda, CA
Background/Purpose: The Southern California Lupus Registry (SCOLR) is a population-based, longitudinal, multi-ethnic cohort of subjects with SLE directed toward studying health and healthcare disparities in…
Abstract Number: 708 • 2017 ACR/ARHP Annual Meeting
Anti-RNP/Sm Antibodies Plus Lupus Anticoagulant As Risk Factor for Thrombosis in Patients with Systemic Lupus Erythematosus
Mari Carmen Zamora-Medina¹, Andrea Hinojosa-Azaola², Carlos Núñez-Álvarez³ and Juanita Romero-Diaz⁴, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutricion S.Z., Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion S.Z., Mexico city, Mexico, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico
Background/Purpose: In a previous study, we identify a potential role of anti-RNP/Sm in combination with LA as risk factor for thrombosis. We aimed to validate…
Abstract Number: 1611 • 2017 ACR/ARHP Annual Meeting
Increased Body Mass Index May Not be a Risk Factor for the Development of Lupus Nephritis
Yu Pei Chock¹, Abhijeet Danve¹, Wei Fu² and Michelle Petri³, ¹Rheumatology, Yale University, New Haven, CT, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD
Background/Purpose: Studies have indicated that increased body mass index (BMI) is a risk factor for development of Chronic Kidney Disease (CKD). Obesity is a low…
Abstract Number: 1838 • 2017 ACR/ARHP Annual Meeting
Estimating Duration of Response in Systemic Lupus Erythematosus (SLE) Trials
Mimi Kim¹, Joan T. Merrill², Kenneth C. Kalunian³, Leslie Hanrahan⁴ and Peter M. Izmirly⁵, ¹Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ⁴Lupus Foundation of America, Washington DC, DC, ⁵Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: The primary endpoint in SLE trials is usually response to therapy at a landmark visit. However, during a trial, patients may alternate between response…
Abstract Number: 2633 • 2017 ACR/ARHP Annual Meeting
Patients with Secondary Sjögren’s Syndrome to SLE Are Characterized By Typical Autoantibodies and a Pro-Inflammatory State
Marika Kvarnstrom¹, Guillermo Ruacho², Johanna Gustafsson³, Agneta Zickert⁴, Vilija Oke⁵, Johan Rönnelid⁶, Kerstin Elvin⁷, Iva Gunnarsson⁸ and Elisabet Svenungsson⁸, ¹Unit of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²Department of Medicine, Unit of Rheumatology,, Stockholm, Sweden, ³Dep. of Medicine, Karolinska Institutet, Karolinska University Hospital, Unit of rheumatology,, Stockholm, Sweden, ⁴Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Department of Medicine, Rheumatology Unit, Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁶Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁷Department of Clinical Immunology and Transfusion Medicine,, 4Unit of Clinical Immunology, Stockholm, Sweden, ⁸Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose :Sjögren´s syndrome occurs in isolation (primary Sjögren´s syndrome, pSS), but it is also often secondary (sSS) to, and sometimes difficult to delineate from, other…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].